Floatz logo

Bortezomib

Parathyroid Carcinoma

Virginia Commonwealth UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Parathyroid Carcinoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Oxodotreotide
M.D. Anderson Cancer Center
Phase 2CCC
Carboplatin
National Cancer Institute (NCI)
Phase 1CC
DACARBAZINE
Virginia Commonwealth University
Phase 1CC

View all 9 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →